After finishing at $3.03 in the prior trading day, Vivos Therapeutics Inc (NASDAQ: VVOS) closed at $2.76, down -9.08%. In other words, the price has decreased by -$0.2750 from its previous closing price. On the day, 5180542 shares were traded.
Ratios:
Our goal is to gain a better understanding of VVOS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.34 and its Current Ratio is at 0.34. In the meantime, Its Debt-to-Equity ratio is 4.88 whereas as Long-Term Debt/Eq ratio is at 3.71.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 20 ’23 when Huntsman Ronald Kirk bought 14,000 shares for $0.53 per share. The transaction valued at 7,420 led to the insider holds 86,521 shares of the business.
Huntsman Ronald Kirk bought 15,000 shares of VVOS for $8,050 on Jun 16 ’23. The Chief Executive Officer now owns 72,521 shares after completing the transaction at $0.54 per share. On Jun 15 ’23, another insider, Huntsman Ronald Kirk, who serves as the Chief Executive Officer of the company, bought 21 shares for $0.50 each. As a result, the insider paid 10 and bolstered with 57,521 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VVOS now has a Market Capitalization of 8.38M and an Enterprise Value of 8.74M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.55 while its Price-to-Book (P/B) ratio in mrq is 12.29. Its current Enterprise Value per Revenue stands at 0.63 whereas that against EBITDA is -0.52.
Stock Price History:
Over the past 52 weeks, VVOS has reached a high of $48.79, while it has fallen to a 52-week low of $2.73. The 50-Day Moving Average of the stock is 4.9428, while the 200-Day Moving Average is calculated to be 7.4346.
Shares Statistics:
The stock has traded on average 131.33K shares per day over the past 3-months and 172.62k shares per day over the last 10 days, according to various share statistics. A total of 2.73M shares are outstanding, with a floating share count of 2.32M. Insiders hold about 15.22% of the company’s shares, while institutions hold 9.41% stake in the company. Shares short for VVOS as of Mar 15, 2024 were 26.18k with a Short Ratio of 0.20, compared to 29.16k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.97% and a Short% of Float of 2.27%.
Earnings Estimates
Its stock is currently analyzed by 2 different market analysts. On average, analysts expect EPS of -$1.17 for the current quarter, with a high estimate of -$1.16 and a low estimate of -$1.19, while EPS last year was -$1.75. The consensus estimate for the next quarter is -$0.92, with high estimates of -$0.79 and low estimates of -$1.05.
Analysts are recommending an EPS of between -$2.85 and -$3.95 for the fiscal current year, implying an average EPS of -$3.4. EPS for the following year is -$2.28, with 2 analysts recommending between -$1.5 and -$3.07.
Revenue Estimates
2 analysts predict $3.41M in revenue for the current quarter. It ranges from a high estimate of $3.5M to a low estimate of $3.32M. As of the current estimate, Vivos Therapeutics Inc’s year-ago sales were $3.86M, an estimated decrease of -11.60% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $3.71M, an increase of 9.30% over than the figure of -$11.60% in the same quarter last year. There is a high estimate of $3.8M for the next quarter, whereas the lowest estimate is $3.62M.
A total of 2 analysts have provided revenue estimates for VVOS’s current fiscal year. The highest revenue estimate was $16.1M, while the lowest revenue estimate was $16M, resulting in an average revenue estimate of $16.05M. In the same quarter a year ago, actual revenue was $13.8M, up 16.30% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $19.11M in the next fiscal year. The high estimate is $19.21M and the low estimate is $19M. The average revenue growth estimate for next year is up 19.10% from the average revenue estimate for this year.
